ARAY and ILMN: Weighing a Turnaround Story Against a Growth Leader
Key Takeaways
- Different scale and sector focus: ARAY is a radiation therapy equipment maker, while ILMN is a genomics and DNA-sequencing leader.
- Diverging momentum: Illumina is in a strong uptrend with accelerating revenue growth, while Accuray is managing a revenue decline and a balance-sheet turnaround.
- Profitability gap: Illumina is solidly profitable with expanding margins; Accuray posted a full-year operating loss and did not issue forward guidance.
- Shared China headwind: Both companies cite geopolitical, tariff, and China demand uncertainty as key risks.
- Catalysts differ: Accuray's story centers on restructuring and new partnerships, while Illumina's centers on clinical sequencing adoption.
Introduction
Investors comparing ARAY and ILMN are weighing two very different healthcare-technology profiles. Accuray supplies robotic radiation therapy systems such as CyberKnife, while Illumina dominates DNA sequencing and genomics analysis. This stock comparison is most relevant to traders and investors assessing relative performance and market positioning between a smaller-cap turnaround candidate and a large-cap growth leader. Although both operate in healthcare and share exposure to China-related risks, their business models, momentum, and risk profiles differ sharply, making them a useful contrast for those evaluating where near-term opportunity and longer-term stability currently sit. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in the industry.
ARAY Overview and Recent Performance
Accuray Incorporated (ARAY) develops precision radiation therapy systems, including CyberKnife and Radixact, for oncology and radiosurgery. In recent market activity, the stock has been volatile, reflecting a company navigating both a financial restructuring and softer product demand. For its fiscal 2026, total revenue fell roughly 12% to about $402 million, with product revenue declining sharply as China sales weakened by roughly $58 million amid tariffs and geopolitical uncertainty. The company swung to a full-year operating loss and reported lower adjusted EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization).
On the positive side, Accuray exceeded its transformation cost-savings target, strengthened its balance sheet through a transaction with TCW that converted debt into equity and added liquidity, and announced collaborations with Samsung to add imaging capabilities to CyberKnife. Service revenue, a more recurring part of the business, grew modestly. However, management withheld formal fiscal 2027 guidance, and order backlog declined, underscoring limited near-term visibility. From what I see, the balance-sheet improvements are worth watching closely.
ILMN Overview and Recent Performance
Illumina (ILMN) provides sequencing and array-based technologies used in oncology, reproductive health, life sciences, and emerging genomics applications. Its shares have delivered a strong rally in recent market activity, with a year-to-date gain well above the broader market, driven by robust clinical sequencing demand and improving profitability. In its most recent quarter, revenue rose about 9.5% year over year, and management raised full-year revenue and adjusted EPS (earnings per share) guidance.
Growth has been led by the NovaSeq X platform and expanding clinical applications, with clinical markets representing a majority of sequencing consumables revenue. Illumina also completed the acquisition of SomaLogic, extending into proteomics. The company carries a moderate debt load with healthy liquidity, and continues share repurchases. Key risks include constrained China demand and a valuation that has drawn debate, as some analysts' price targets sit below the current share price after the stock's sharp advance. I’m watching this closely as clinical adoption continues to build.
Head-to-Head Comparison
The core contrast between ARAY and ILMN is scale and stage. Illumina generates roughly $4.6 billion in annual revenue with positive earnings and expanding margins, while Accuray generates about $400 million and is working to restore profitability. Their growth drivers also differ: Illumina benefits from rising sequencing intensity and a large installed base that supports recurring consumables, whereas Accuray depends on capital-equipment orders that are more cyclical and exposed to hospital budgeting.
On momentum, Illumina has clear relative strength, while Accuray's trajectory is more uncertain as it digests a restructuring and lacks forward guidance. Risk profiles diverge as well: Illumina's chief risks are China regulation and a potentially stretched valuation, while Accuray faces leverage reduction, thinner margins, and order visibility. Both carry sector exposure to healthcare and to China-related headwinds, but their market sentiment currently reflects opposite phases of the cycle.
Tickeron AI Verdict
Based on observable factors such as trend consistency, revenue trajectory, and earnings stability, Tickeron's AI would currently lean toward ILMN as the more favorable of the two. Illumina exhibits stronger and more durable upward momentum, positive profitability, and a clearer growth catalyst in clinical sequencing, whereas Accuray's setup is more event-driven and dependent on a still-unfolding turnaround. This assessment is probabilistic rather than definitive: Accuray's partnerships and restructuring could improve its positioning, while Illumina's elevated valuation introduces downside risk. The AI verdict favors the stock with steadier trend signals and stronger fundamentals today.
Exploring AI-Driven Strategies
When comparing names like these, I often turn to Tickeron’s Trending AI Robots page for a curated view of automated strategies. Tickeron hosts hundreds of AI Trading Bots that trade thousands of different tickers, each with its own trading style, timeframe, performance statistics, and basket of securities. Because not every bot suits every market condition, only the strongest and most relevant strategies are featured in the Trending AI Robots section. These bots vary widely in approach, from short-term swing trades to longer-horizon trend-following models, allowing users to explore options aligned with their objectives.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Aroon Indicator for ILMN shows an upward move is likely
ILMN's Aroon Indicator triggered a bullish signal on September 24, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 213 similar instances where the Aroon Indicator showed a similar pattern. In 183 of the 213 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 15, 2026. You may want to consider a long position or call options on ILMN as a result. In 74 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for ILMN just turned positive on September 16, 2026. Looking at past instances where ILMN's MACD turned positive, the stock continued to rise in 42 of 55 cases over the following month. The odds of a continued upward trend are 76%.
Following a +0.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where ILMN advanced for three days, in 200 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ILMN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
ILMN broke above its upper Bollinger Band on September 24, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 6 (best 1 - 100 worst), indicating outstanding price growth. ILMN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 31 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 77 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.472) is normal, around the industry mean (72.578). P/E Ratio (50.728) is within average values for comparable stocks, (146.993). Projected Growth (PEG Ratio) (3.355) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.001) among similar stocks. P/S Ratio (7.843) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ILMN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of integrated systems for the analysis of genetic variation and function
Industry MedicalSpecialties